BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 33722826)

  • 1. Cardiotoxicities of novel cancer immunotherapies.
    Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
    Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
    Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
    Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicities associated with immune checkpoint inhibitors.
    Yang S; Asnani A
    Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular toxicity of immune therapies for cancer.
    Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
    BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
    Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
    Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
    Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
    J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
    Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
    J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
    Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
    Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular toxicities associated with immune checkpoint inhibitors.
    Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
    Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity of Immune Therapy.
    Ganatra S; Parikh R; Neilan TG
    Cardiol Clin; 2019 Nov; 37(4):385-397. PubMed ID: 31587780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of Contemporary Anticancer Immunotherapy.
    Dal'bo N; Patel R; Parikh R; Shah SP; Guha A; Dani SS; Ganatra S
    Curr Treat Options Cardiovasc Med; 2020; 22(12):62. PubMed ID: 33162729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
    Gill J
    Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
    Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
    Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.
    Ala CK; Klein AL; Moslehi JJ
    Curr Cardiol Rep; 2019 Nov; 21(12):156. PubMed ID: 31768769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
    Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell Immunotherapy and Cardiovascular Disease: Chimeric Antigen Receptor T-cell and Bispecific T-cell Engager Therapies.
    Stein-Merlob AF; Ganatra S; Yang EH
    Heart Fail Clin; 2022 Jul; 18(3):443-454. PubMed ID: 35718418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.